Nektar Therapeutics (NKTR)
Health Care ยท Pharmaceutical Preparations
Nektar Therapeutics (NKTR) is listed on Nasdaq, where its shares have traded since May 3, 1994. SentiSense covers Nektar Therapeutics in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Howard W. Robin is its chief executive officer. The company reports 63 employees, and its corporate website is www.nektar.com.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 234 institutions reported holding NKTR, with 35.9 million shares worth $2.5 billion in aggregate. The largest reported holders were FMR, Two Seas Capital and BlackRock. Of the 5 largest reported holders, 4 added shares and 1 reduced its position during the quarter.
More on NKTR
- NKTR sentiment: whether news and social coverage of Nektar Therapeutics leans bullish or bearish, and the stories driving it.
- NKTR ownership: all 234 reporting institutions, plus insider and congressional trades.
- NKTR financials: revenue, net income, operating margin and free cash flow by quarter and year.
SentiSense also tracks daily options readings for Nektar Therapeutics: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Nektar Therapeutics do?
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy.
What sector is NKTR in?
SentiSense classifies Nektar Therapeutics in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does NKTR stock trade?
Nektar Therapeutics (NKTR) is listed on Nasdaq, where its shares have traded since May 3, 1994.
Who is the CEO of Nektar Therapeutics?
Howard W. Robin is the chief executive officer of Nektar Therapeutics.